Tissue inhibitor of matrix metalloprotinase-1 and collagen type IV in HCV-associated cirrhosis and grading of esophageal varices

Abdalla, Nasser Mohamed; El Aziz, Fatma Mohamed Abd; Deghady, Akram; Abaza, Mohamed Helmy; Ellakany, Walid Ismail

doi:10.1186/s43066-024-00316-9

Egyptian Liver Journal

Table 2 Comparison between the three studied groups according to laboratory investigations

From: Tissue inhibitor of matrix metalloprotinase-1 and collagen type IV in HCV-associated cirrhosis and grading of esophageal varices

	Group 1 (n = 30)	Group 2 (n = 60)	Control (n = 30)	Test of Sig. (p)	Sig. bet. grps.
Hemoglobin
Min.–Max.	11.60–13.10	8.30–11.40	11.70–14.50	F = 217.650^* p < 0.001^*	p₁ < 0.001^, p₂ = 0.002^, p₃ < 0.001^*
Mean ± SD.	12.45 ± 0.43	10.23 ± 0.73	13.07 ± 0.76
Median (IQR)	12.45 (12.30–12.70)	10.40 (9.80–10.75)	13.20 (12.20–13.40)
WBC
Min.–Max.	4.0–9.0	2.70–9.0	6.0–9.0	F = 20.804^* p < 0.001^*	p₁ = 0.183, p₂ < 0.001^, p₃ < 0.001^
Mean ± SD.	5.75 ± 1.43	5.17 ± 1.66	7.26 ± 0.95
Median (IQR)	5.50 (4.50–7.0)	5.10 (3.70–6.35)	7.10 (6.50–8.0)
Platelets
Min.–Max.	144.0–185.0	42.0–186.0	230.0–409.0	F = 193.65^* p < 0.001^*	p₁ < 0.001^, p₂ < 0.001^, p₃ < 0.001^*
Mean ± SD.	163.8 ± 12.77	116.3 ± 41.23	286.2 ± 49.11
Median (IQR)	160.0 (156.0–172.0)	129.0 (75.50–147.5)	278.0 (242.0–319.0)
Urea
Min.–Max.	9.0–35.0	18.0–59.0	13.0–34.0	F = 82.125^* p < 0.001^*	p₁ < 0.001^, p₂ = 0.995, p₃ < 0.001^
Mean ± SD.	21.0 ± 8.11	42.45 ± 10.38	21.23 ± 7.08
Median (IQR)	20.50 (14.0–28.0)	44.0 (35.0–51.0)	21.0 (15.0–27.0)
Creatinine
Min.–Max.	0.60–1.20	0.70–1.60	0.70–1.30	F = 40.559^* p < 0.001^*	p₁ < 0.001^, p₂ = 0.069, p₃ < 0.001^
Mean ± SD.	0.89 ± 0.17	1.27 ± 0.22	1.01 ± 0.19
Median (IQR)	0.90 (0.80–1.0)	1.30 (1.15–1.40)	1.0 (0.90–1.20)
Total bilirubin
Min.–Max.	0.90–1.70	1.0–5.70	0.30–1.0	H = 78.057^* p < 0.001^*	p₁ < 0.001^, p₂ < 0.001^, p₃ < 0.001^*
Mean ± SD.	1.35 ± 0.28	2.62 ± 1.54	0.68 ± 0.21
Median (IQR)	1.40 (1.10–1.60)	1.70 (1.50–4.15)	0.70 (0.50–0.80)
Direct bilirubin
Min.–Max.	0.50–1.20	0.60–4.40	0.20–0.80	H = 67.286^* p < 0.001^*	p₁ < 0.001^, p₂ < 0.001^, p₃ < 0.001^*
Mean ± SD.	0.86 ± 0.25	1.78 ± 1.13	0.48 ± 0.19
Median (IQR)	0.90 (0.60–1.10)	1.20 (1.0–2.85)	0.40 (0.30–0.70)
ALT
Min.–Max.	9.0–98.0	12.0–124.0	16.0–32.0	H = 32.049^* p < 0.001^*	p₁ = 0.006^, p₂ = 0.013^, p₃ < 0.001^*
Mean ± SD.	37.93 ± 25.74	51.28 ± 28.89	23.90 ± 4.45
Median (IQR)	29.0 (23.0–54.0)	39.50 (29.0–73.5)	22.50 (21.0–27.0)
AST
Min.–Max.	41.0–131.0	32.0–124.0	12.0–29.0	F = 90.793^* p < 0.001^*	p₁ = 1.000, p₂ < 0.001^, p₃ < 0.001^
Mean ± SD.	74.13 ± 24.36	74.15 ± 21.57	18.27 ± 4.53
Median (IQR)	73.50 (51.0–97.0)	72.0 (58.50–88.5)	17.0 (15.0–21.0)
AST/ALT ratio
Min.–Max.	1.27–4.89	0.77–4.08	0.48–1.0	H = 71.431^* p < 0.001^*	p₁ = 0.004^, p₂ < 0.001^, p₃ < 0.001^*
Mean ± SD.	2.49 ± 0.99	1.74 ± 0.72	0.77 ± 0.12
Median (IQR)	2.23 (1.80–3.07)	1.51 (1.18–2.25)	0.74 (0.68–0.86)
Albumin
Min.–Max.	3.20–4.60	2.10–4.20	3.90–4.50	F = 93.250^* p < 0.001^*	p₁ < 0.001^, p₂ = 0.138, p₃ < 0.001^
Mean ± SD.	3.96 ± 0.42	2.92 ± 0.58	4.20 ± 0.18
Median (IQR)	4.0 (3.70–4.30)	2.85 (2.50–3.20)	4.20 (4.0–4.30)
INR
Min.–Max.	1.10–1.42	1.20–1.60	1.0–1.20	F = 135.49^* p < 0.001^*	p₁ < 0.001^, p₂ < 0.001^, p₃ < 0.001^*
Mean ± SD.	1.22 ± 0.11	1.40 ± 0.11	1.04 ± 0.07
Median (IQR)	1.20 (1.10–1.31)	1.40 (1.30–1.45)	1.0 (1.0–1.10)

IQR interquartile range, SD standard deviation, F F for one-way ANOVA test, pairwise comparison bet. each 2 groups was done using Post Hoc Test (Tukey)
H: H for Kruskal Wallis test, Pairwise comparison bet. each 2 groups was done using Post Hoc Test (Dunn’s for multiple comparisons test)
p: p value for comparing between the three studied groups; p1: p value for comparing between group 1 and group 2
p2: p value for comparing between group 1 and control; p3: p value for comparing between group 2 and control
* Statistically significant at p ≤ 0.05

Back to article page